HPV Genotyping of Modified General Primer-Amplicons Is More Analytically Sensitive and Specific by Sequencing than by Hybridization

PLoS One. 2017 Jan 3;12(1):e0169074. doi: 10.1371/journal.pone.0169074. eCollection 2017.

Abstract

Sensitive and specific genotyping of human papillomaviruses (HPVs) is important for population-based surveillance of carcinogenic HPV types and for monitoring vaccine effectiveness. Here we compare HPV genotyping by Next Generation Sequencing (NGS) to an established DNA hybridization method. In DNA isolated from urine, the overall analytical sensitivity of NGS was found to be 22% higher than that of hybridization. NGS was also found to be the most specific method and expanded the detection repertoire beyond the 37 types of the DNA hybridization assay. Furthermore, NGS provided an increased resolution by identifying genetic variants of individual HPV types. The same Modified General Primers (MGP)-amplicon was used in both methods. The NGS method is described in detail to facilitate implementation in the clinical microbiology laboratory and includes suggestions for new standards for detection and calling of types and variants with improved resolution.

MeSH terms

  • Adolescent
  • Adult
  • Chlamydia Infections
  • DNA Primers / genetics*
  • DNA, Viral / genetics
  • Female
  • Genetic Variation
  • Genotyping Techniques / methods
  • High-Throughput Nucleotide Sequencing / methods*
  • Humans
  • Hybridization, Genetic
  • Nucleic Acid Hybridization*
  • Papillomaviridae / genetics*
  • Papillomavirus Infections / diagnosis
  • Papillomavirus Infections / virology*
  • Sensitivity and Specificity
  • Uterine Cervical Neoplasms / diagnosis
  • Uterine Cervical Neoplasms / virology*
  • Young Adult

Substances

  • DNA Primers
  • DNA, Viral

Grants and funding

Head of Dept. Merete Holth and the Dept. Microbiology and Infection Control for additional financial support. The majority of the work was funded by a Norwegian governmental grant to the National Institute of Public Health for the national surveillance of the HPV vaccination program.